Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
215597-83-4
82436-77-9
135661-44-8
162823-01-0
127634-19-9
152305-87-8
70057-64-6 | 5-(3,5-dichlorophenyl)-1,3,4-thiadiazol-2-amine | AA00JSV5 | MFCD03041015
1270367-30-0 | tert-butyl N-[2-amino-2-(naphthalen-2-yl)ethyl]carbamate | AA00JWEK | MFCD18657743
1208075-42-6 | 2-methyl-3-(trifluoromethyl)benzene-1-thiol | AA00KPE8 | MFCD12026168
370-45-6 | 2-(3-fluorophenyl)acetamide | AA00MOI2 | MFCD11503406
1429180-99-3 | (S)-3-(2-Chloro-6-methyl-4-pyrimidyl)-4-isopropyl-2-oxazolidinone | AA00QS96 | MFCD30723197
945-03-9 | (2-Oxo-1,3-benzothiazol-3(2h)-yl)acetic acid | AA00VRTY | MFCD00796503
22278-11-1 | 3-(Piperazin-1-yl)propanoic acid dihydrochloride | AA00VT16 | MFCD02093542
98027-63-5 | 5-Sulfamoylfuran-2-carboxylic acid | AA00VUFT | MFCD09037277
56716-98-4 | 2-methyl-6-phenoxyquinolin-4-ol | AA00VW3J | MFCD03847529
685113-09-1 | (5-morpholin-4-yl-2H-tetraazol-2-yl)acetic acid | AA0169O2 | MFCD00268695